Abstract
Background Interleukin-6 (IL6) signaling is a key inflammatory pathway widely implicated in the pathogenesis of multiple diseases including autoimmune, vascular, and metabolic disorders. While IL6-receptor (IL6R) inhibitors are already in use for the treatment of autoimmune diseases, their repurposing potential and safety profile is still debated.
Methods We used 7 genetic variants at the IL6R locus as proxies for IL6 signaling downregulation and explored their effects on 1,428 clinical outcomes in a phenome-wide association study (PheWAS) using data from the UK Biobank (339,256 unrelated individuals). Significant associations were meta-analyzed with data from the Penn Medicine (10,244 individuals) and BioMe (9,054 individuals) Biobanks for validation. We further investigated associations between genetically downregulated IL6 signaling and 366 biomarkers and endophenotypes of human disease in the UK Biobank and other phenotype-specific consortia. All associations were examined by Mendelian randomization (MR) analyses scaled to the effects of tocilizumab, a monoclonal antibody targeting IL6R.
Results The PheWAS-MR analyses showed significant associations with 16 clinical outcomes and 17 biomarkers following correction for multiple comparisons. Genetically downregulated IL6 signaling was associated with a lower risk of several atherosclerotic phenotypes including ischemic heart disease (OR: 0.84, 95%CI: 0.77-0.90) and abdominal aortic aneurysm (OR: 0.44, 95%CI: 0.29-0.67). We further found significant associations with lower risk of type 2 diabetes (OR: 0.80, 95%CI: 0.73-0.88), lower glycated hemoglobin A1c (HbA1c) levels (beta: −0.07, 95%CI: −0.08 to −0.05), and higher HDL-cholesterol levels (beta: 0.04, 95%CI: 0.02-0.06). In accord with clinical trials examining pharmacological IL6 blockade, genetically downregulated IL6 signaling was associated with higher risk of neutropenia and bacterial infections (cellulitis and urinary tract infections) and with higher hemoglobin concentrations. We further found significant associations with higher risk of atopic dermatitis and higher levels of the pro-allergic cytokine interleukin-4.
Conclusions Genetic IL6 signaling downregulation associates with a lower risk of vascular outcomes and a more favorable cardiometabolic profile. These findings further support a repurposing of IL6R blockade for lowering cardiovascular risk while also informing on potential side effects.
Competing Interest Statement
Dr Gill is employed part-time by Novo Nordisk. The other authors have no conflicts of interest to disclose.
Funding Statement
M. Georgakis has received funding from the Onassis Foundation. D. Gill was supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. S. Damrauer is supported by the US Department of Veterans Affairs (IK2/CX001780). This work does not express the vies of the US Department of Veterans Affairs or the US Government. E. Theodoratou is funded by CRUK (C31250/A22804). This project has received funding from the European Union Horizon 2020 research and innovation programme (666881), SVDs@target (to MD, 667375), CoSTREAM (to MD), the DFG as part of the Munich Cluster for Systems Neurology (EXC/2145 SyNergy / ID 390857198) and the CRC 1123 (B3, to MD), the Corona Foundation (to MD), the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain, to MD), the eMed program (eAtheroSysMed, to MD) and the FP7/2007/2103 European Union project CVgenes@target (grant agreement number Health/F2/2013/601456, to MD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants in all studies provided informed consent and all studies obtained ethical approval from institutional review boards. We accessed individual-level data from the UK Biobank data following approval of an application by the UK Biobank Ethics and Governance Council (application #2532). For the Penn Medicine and BioMe Biobanks, individual-level data were analyzed from investigators of the studies (ML, RJ, MR, SV, SD for Penn Medicine and HMV, GN for BioMe) after receiving approval for the current study from the University of Pennsylvania Institutional Review Board and the Institutional Review Board of the Icahn School of Medicine, respectively. We then accessed the derived summary statistics to meta-analyze them with the UK Biobank data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The genetic variants used as instruments in the current study, as well as summary statistics derived for the examined outcomes are available as Supplementary Material. Raw UK Biobank data may be derived through application. Data from the Penn Medicine and BioMe Biobanks are also available upon application to principal investigators.
